INVESTER I NEOVACS MED ENDAVU: Køb Neovacs ($0LW1) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Neovacs, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Neovacs S.A. is a biotechnology company focused on developing therapeutic vaccines for immune-related diseases. Its research platform centers on Kinoid technology, designed to stimulate the immune system to produce targeted polyclonal antibodies against disease-associated biological factors. The company’s current focus spans autoimmune and inflammatory disorders, allergies, and selected oncology applications, placing it within the specialized biopharmaceutical and medical research sectors. Neovacs S.A. operates at the intersection of immunology, vaccine development, and therapeutic innovation, addressing conditions in which abnormal immune activity contributes to disease progression. Its work is oriented toward creating biological treatments that may support more targeted disease management than conventional approaches. Through its research programs and technology platform, Neovacs S.A. represents a development-stage participant in the biotechnology market, where scientific discovery, clinical validation, and regulatory requirements shape the path from laboratory research to potential medical use.